This finding suggests that, at least in mice, systemic AhR activation can dissociate the severity of liver steatosis from insulin sensitivity, and that intake of natural AhR ligand should be carefully evaluated in NASH patients. This evidence concerns the gene AHR and metabolic dysfunction-associated steatohepatitis.